Pharmaceutics

We report a novel formulation approach for development of a thermostable oral insulin tablet. Using freeze drying to form a heat stable tablet in a single-step process, we demonstrate hydroxypropyl beta cyclodextrin (HP-{beta}-CD) encapsulated lipophilic ion-pair complex of insulin using bile salt achieves intestinal absorption and sustained glucose levels. The tablets produced using this simple approach with only two excipients offer protection from enzymatic and stomach acid degradation and facilitate insulin uptake, without any need for specialized drug manufacturing or enteric coating. Insulin in this innovative formulation is thermotolerant, capable of maintaining stability even under heat stress at 30-40{degrees}C/65-75% RH. The convenient presentation of insulin as a thermostable oral tablet presents a low-cost scalable manufacturing method that simplifies the logistics of storage, transport, and distribution in any setting, including areas where cold storage maybe limited or unavailable. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=141 SRC="FIGDIR/small/635377v1_ufig1.gif" ALT="Figure 1"> View larger version (40K): org.highwire.dtl.DTLVardef@16b4b64org.highwire.dtl.DTLVardef@122c11forg.highwire.dtl.DTLVardef@b50c0borg.highwire.dtl.DTLVardef@29bf28_HPS_FORMAT_FIGEXP M_FIG Our unique formulation approach protects insulin from stomach and temperature induced degradation, improves intestinal permeability providing a sustained release of insulin for glycemic control. The freeze dried tablet product format is easily scalable and flexible, increasing accessibility across all populations. C_FIG

As of today seven coronaviruses were identified to infect humans, out of which only 4 of them belongs to beta family of coronavirus, like HCoV-HKU1, SARS-CoV-2, MERS-CoV and SARS-CoV. SARS family of viruses were known to cause severe respiratory disease in humans. SARS-CoV-2 infection causes pandemic COVID-19 disease with high morbidity and mortality. Remdesivir (RDV) is the only antiviral drug so far approved for Covid-19 therapy by FDA. However its efficacy is limited in vivo due to its low stability in presence of Plasma. Here we show the stability of RDV encapsulated with our platform technology based polymer NV-387 (NV-CoV-2-R), in presence of Plasma in vitro in comparison to naked RDV when incubated in plasma. The potential use of this polymer in vivo will be discussed, here.

Chronic diseases often require repeated oral or local administration, which can compromise patient compliance. In wet age-related macular degeneration (AMD), current therapies rely on intravitreal injections of anti-vascular endothelial growth factor agents every four to six weeks to maintain therapeutic drug levels. Controlled-release drug delivery systems offer a promising alternative by reducing injection frequency and extending drug release. In this study, we developed a continuum diffusion model to describe drug transport through porous polymeric microcapsules, implemented using the finite element method in COMSOL Multiphysics. The case study focused on cylindrical microcapsules fabricated with either a single polycaprolactone (PCL) layer or a bi-layered chitosan-PCL structure, tested at two capsule sizes and three salt leaching concentrations. Bovine serum albumin and bevacizumab were used as model drugs. Parameter estimation was performed using published release data, with a progressive fitting strategy that carried forward parameters from simpler systems into more complex designs. The model reproduced experimental release profiles across formulations and identified key transport parameters governing release dynamics, including porosity, tortuosity, and mass transfer rates. Design exploration revealed that polymer thickness was the dominant factor controlling release, while addition of the chitosan layer moderated the initial burst and extended therapeutic delivery. This framework demonstrates how computational modeling can reduce experimental burden, guide design optimization, and support the development of long-acting intravitreal drug delivery systems to treat wet AMD by linking drug release kinetics to design variables.

Glioblastoma (GBM) is a malignant brain tumor with a poor long-term prognosis. The current median survival is approximately fifteen to twenty months with the standard of care therapy which includes surgery, radiation, and chemotherapy. An important factor contributing to recurrence of GBM is high resistance of GBM cancer stem cells (CSCs) to several anticancer drugs, for which a systemically delivered single drug approach will be unlikely to produce a viable cure. Therefore, multidrug therapies have the potential to improve the survival time. Currently, only temozolomide (TMZ), which is a DNA alkylator, affects overall survival in GBM patients. CSCs regenerate rapidly and over-express a methyl transferase which overrides the DNA-alkylating mechanism of TMZ, leading to drug resistance. Idasanutlin (RG7388, R05503781) is a potent, selective MDM2 antagonist that additively kills GBM CSCs when combined with TMZ. Nanotechnology is an emerging field that shows great promise in drug delivery and diagnostics. The ability to combine both therapy and imaging allows real time assessment of drug delivery in vivo for the field of theranostics. To develop a multi-drug therapy using multi-functional nanoparticles (NPs) that preferentially target the GBM CSC subpopulation and provide in vivo preclinical imaging capability. Polymer-micellar NPs composed of poly(styrene-b-ethylene oxide) (PS-b-PEO) and poly(lactic-co-glycolic) acid (PLGA) were developed investigating both single and double emulsion fabrication techniques as well as combinations of TMZ and RG7388. The NPs were covalently bound to a 15-base-pair CD133 aptamer in order to target the CD133 antigen expressed on the surface of GBM CSC subpopulation. For theranostic functionality, the NPs were also labelled with a radiotracer, Zirconium-89 (89Zr). The NPs maintained a small size of less than 100 nm, a low negative charge and exhibited the ability to effectively target and kill the CSC subpopulation. In addition, the conjugation of the CD133 aptamer was able to promote killing in CSCs leading to the justification of a targeted nanosystem to potentially improve localized therapy in future in vivo models. This work has provided a potentially therapeutic option for GBM specific for CSC targeting and theranostic imaging.

Background: Gadolinium-based contrast agents (GBCAs) are routinely used in magnetic resonance imaging (MRI). Although macrocyclic GBCAs were initially considered biologically inert, it is now known that a fraction of patients retains gadolinium (Gd) for prolonged periods in tissues such as blood, bone, and brain. Because the first cellular interactions of GBCAs occur in the bloodstream, this study aimed to elucidate the uptake mechanism but also the intracellular persistence and release dynamics of gadoterate meglumine, one of the most widely used macrocyclic agents, in white blood cells (WBCs). Methodology and principal findings: WBCs and K562 cells were incubated with gadoterate meglumine under different conditions to investigate its cellular entry mechanisms. Uptake of the contrast agent was quantified by measuring intracellular Gd using single-cell inductively coupled plasma mass spectrometry (SC-ICP-MS). Time and concentration-dependent incubation of K562 cells revealed saturable uptake kinetics consistent with a Michaelis-Menten model which is independent of the phase of the cell cycle. Gadoterate meglumine uptake in both WBCs and K562 cells was shown to be an active process, as uptake was strongly reduced or abolished at low temperature (16C and 4C) and in the presence of metabolic inhibitors (sodium azide and 2-deoxyglucose). Co-incubation with multiple endocytosis inhibitors (Dyngo 4a, Dynole 2-24 and chlorpromazine) did not significantly decrease intracellular Gd levels in K562 cells and caused only a slight reduction in WBCs, indicating that endocytosis is not the main entry pathway for gadoterate meglumine in these cells. Furthermore, we assessed the retention time of the Gd inside the cells, showing that only after 24 hours post incubation 80% percent of the intracellular Gd was released through an active process. Finally, we demonstrate that one of the mechanisms of Gd release from WBCs involves extracellular vesicles, which may substantially increase its potential for downstream accumulation in different tissues, including immunoprivileged tissues like brain. Significance: The observed time-dependent accumulation, temperature and energy dependence of gadoterate meglumine uptake demonstrate that active cellular mechanisms are primarily responsible for GBCA internalization. Furthermore, our results indicate that macropinocytosis, phagocytosis, and clathrin-mediated endocytosis are not the primary routes of gadoterate meglumine entry. Hereby, we also describe that Gd externalization is an active process involving extracellular vesicles which may influence the Gd distribution in different tissues and its consequent long-term retention. Further studies are required to explore strategies to block this process in order to mitigate potential long-term gadolinium retention.

Extracellular vesicles (EVs) are promising nanocarriers for therapeutic delivery; however, the factors governing EV uptake by recipient cells remain incompletely understood. In this study, we investigated whether EV internalization is primarily influenced by donor-cell origin or recipient-cell phenotype. Fluorescently labeled EVs derived from HEK293T, or SKBR-3 cells were incubated with a range of human epithelial, immune, and murine cancer cell lines at different doses and time points. HEK293T-derived EVs showed highly variable uptake across recipient cells, with hepatocellular carcinoma cell lines Huh7 and HepG2 exhibiting the highest internalization, while parental HEK293T cells showed the lowest. THP-1 immune cells also demonstrated strong uptake, whereas Jurkat cells showed moderate uptake. In murine melanoma models, Yummer cells internalized more EVs than B16F10 cells. Importantly, similar uptake trends were observed using SKBR-3-derived EVs, where Huh7 and HepG2 again displayed the highest uptake despite originating from a different donor cell source. EV internalization increased with dose and incubation time until saturation at higher concentrations. Together, these results demonstrate that EV uptake is predominantly determined by recipient-cell characteristics rather than EV source. These findings provide important mechanistic insight for the development of EV-based therapeutics and suggest that optimizing recipient-cell targeting is essential for efficient vesicle-mediated delivery. Graphical abstractEV uptake is determined by cell membrane properties rather than by the source of the EVs. The image was created by Biorender. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=122 SRC="FIGDIR/small/726167v1_ufig1.gif" ALT="Figure 1"> View larger version (29K): org.highwire.dtl.DTLVardef@f5c1cborg.highwire.dtl.DTLVardef@860962org.highwire.dtl.DTLVardef@1d20239org.highwire.dtl.DTLVardef@9003af_HPS_FORMAT_FIGEXP M_FIG C_FIG

PurposeDespite advances in oral and injectable HIV prevention options and oral prophylaxis for sexually transmitted infections (STIs) of bacterial origin, there remains a critical need for effective on-demand topical (vaginal/rectal) products for pre- and post-exposure prophylaxis (PrEP and PEP). To fill this gap, we have developed single and first-in-kind multi-active topical inserts for bacterial STIs and HIV/STIs prevention. MethodsWe have formulated two different inserts, one containing doxycycline (DOX) at 10, 50, and 100mg doses for bacterial STI prevention, and a multipurpose prevention product (TED insert) that combines DOX (10mg) with the antiretrovirals tenofovir alafenamide (TAF; 20mg) and elvitegravir (EVG; 16mg) to target both bacterial STIs and HIV. ResultsInserts were manufactured through a simple, cost-effective process. Drug loading was within 95-105% of the labeled amount, confirming a robust manufacturing process. In vitro, they disintegrated within 10min with >95% drug release within 60min. The dissolution behavior of DOX inserts showed surface erosion but was affected by medium volume and drug amount. The inserts met key physicochemical targets: hardness (5-8kg), friability (<1%), moisture content (<2%), and osmolality (<550mOsm/kg). Based on 6-month storage stability, DOX inserts maintained their physicochemical properties, suggesting a shelf life of >2years. Preliminary 1-month stability of TED inserts under accelerated conditions showed preservation of their physicochemical properties. ConclusionThis study represents the first formulation development report on topical inserts containing DOX alone or in combination with antiretrovirals. Both inserts offer a novel, on-demand topical STI prevention option that supports flexible PrEP/PEP use by both women and men.

This work develops and characterises a hierachichal oral drug delivery system based on the microencpasulation of drug-loaded amphiphilic nanogels within a mucoadhesive alginate/chitosan shell. Results show a more controlled release and a statistically significant oral half-life with respect to the free drug.

Despite progress made in the development of anticancer therapeutics, traditional small-molecule chemotherapeutics often struggle to overcome toxicity, efficacy, and off-target effects. These specific issues can be overcome by either encapsulating the drug or by targeting it directly to the tumor cell. Here, we describe a novel targeted nanoparticle (referred to as a nano-antibody-drug conjugate Targeted Nanosphere or nADC/TNS), based cancer therapeutic platform that can improve the efficacy of a broad range of existing therapeutics. Targeting is antibody-directed, as with antibody-drug conjugates (ADCs). Still, the payload per antibody is vastly greater by orders of magnitude (a thousand for nADC/TNS versus two to eight for ADCs). The nADC/TNS consists of an approximately 80 nm drug-filled nanoparticle composed of phospholipids, cholesterol, and UV cross-linkable diacetylene lipids. We describe the preparation, characterization, and evaluation of nADC/TNS as a novel, versatile, and effective treatment modality for cancer and potentially other diseases. This report focuses on data with nADC/TNS variants NV101 (anti-CD99 targeted, doxorubicin-filled), NV102 (anti-CD19 targeted, doxorubicin-filled), and NV103 (anti-CD99 targeted, irinotecan-filled). We investigated NV101 and NV103 in a mouse model with implanted and metastatic Ewing tumors (ES). NV101 demonstrated significant tumor burden reduction while NV103 induced complete ablation of ES tumors. NV102 demonstrated complete ablation of chemotherapy-resistant relapsed adult lymphocytic leukemia (ALL). These results document the potential superior efficacy of antibody-targeted nanoparticles containing a variety of small-molecule payloads, compared to their free molecule equivalents.

Antenatal depression, or depression during pregnancy, is a common psychiatric disorder and poses significant risks to both the mother and the fetus. Despite these risks, it is frequently left untreated due to fears of side effects caused by antidepressant medications which cross through the placental barrier. It is therefore desirable to develop formulation strategies to mitigate systemic exposure to relevant drug molecules while maintaining their psychotropic efficacy. In this work, we develop formulations of sertraline, a common antidepressant, to target delivery to the brain through intranasal administration. Formulation engineering enables successful solubilization of sertraline at high concentrations and our lead formulation remains stable at room temperature for months. Using mice, we compare sertraline biodistribution following intranasal administration and standard oral administration. Intranasal administration of our drug product candidate provides comparable brain exposure at half the dose compared to oral treatment and lowers the maximum plasma exposure. These findings suggest that intranasal administration may provide selectivity for drug exposure in the central nervous system over systemic exposure.

This study was conducted with the primary objective of improving the bioavailability of aripiprazole (APZ) through the development of nanoparticles using thiolated arabinoxylan (TAX) sourced from corn husk. TAX was synthesized via thiolation, employing thiourea as a thiol donor and hydrochloric acid as a catalyst. Characterization of TAX revealed a surface free thiol group content of 37.461 mmol/g, accompanied by an angle of repose measuring 0.393{+/-}0.035. Bulk density, tapped density, Hausner ratio, and Carr index fell within prescribed limits. Subsequently, APZ-loaded thiolated arabinoxylan based nanoparticles were fabricated using the ionotropic gelation method, with barium chloride serving as a cross-linker. Encapsulation efficiency was highest for formulation F4, at 97.1%{+/-}2.36. In vitro drug release demonstrated sustained release profiles at both pH 1.2 and pH 6.8, with F4 exhibiting the most favourable release kinetics. In vitro, characterization indicated that the optimized thiolated arabinoxylan based nanoparticle formulation had an average particle size of 211.1 nm with a Polydispersity Index (PDI) of 0.092 and a zeta potential of 0.621 mV. SEM imaging showed uniform, slightly spherical particles with minimal pores. DSC and TGA confirmed the conversion of APZ to amorphous states within the nanoparticles, enhancing solubility. Ex-vivo permeation studies exhibited favourable drug permeation. An In-vivo pharmacodynamics studies in a ketamine-induced schizophrenia rat model indicated the effectiveness of APZ loaded thiolated arabinoxylan based nanoparticles in behavioural tests, with no significant cataplectic effects observed. Acute oral toxicity assessments demonstrated the safety, with no mortality, no significant alterations in food and water consumption, or any histopathological abnormalities. In conclusion, these developed APZ-loaded thiolated arabinoxylan based nanoparticles hold promise for the effective treatment of schizophrenia without inducing toxic effects, showcasing their potential for clinical applications.

Advancement and implementation of nanoparticle-based systems for enhanced drug delivery have become essential for the suppression of viral pathogens due to lack of viable treatment options. This study focuses on characterization and application of mPEG-PCL co-polymers for development of pH-responsive, biodegradable micellar nanoparticles (MNPs) for the delivery of the antiviral drug ribavirin against Zika virus. Synthesis of mPEG-PCL diblock copolymers was confirmed through FTIR and 1H NMR, which validated the formation of ester functional groups and accurate structure of copolymers. mPEG-PCL MNPs, loaded with ribavirin, exhibited a mean diameter of approximately 34.29 {+/-} 5.214 nm and a zeta potential of -3.28 {+/-} 0.718 mV, suitable for evading immune detection and facilitating cellular entry. The ribavirin-loaded mPEG-PCL MNPs demonstrated pH-dependent release, with approximately 88% of ribavirin released at pH 5.5, compared to 20% at pH 7.4. This pH-responsive release is crucial for targeted drug delivery within the endosomal pathway. In vitro studies using JEG-3 cells infected with Zika virus showed that ribavirin-loaded mPEG-PCL MNPs achieved an EC50 of 0.22nM, significantly enhancing drug efficacy compared to unencapsulated ribavirin, which required micromolar concentrations to achieve similar effects. The MTT assay results indicated minimal cytotoxicity of the ribavirin-loaded mPEG-PCL MNPs, with approximately 80% cell viability at the highest concentration evaluated. Confocal microscopy and RT-PCR analysis further confirmed the efficient cellular uptake and potent antiviral activity of the ribavirin-loaded MNPs. These findings highlight the potential of mPEG-PCL MNPs as an effective delivery system for broad-spectrum antivirals like ribavirin, enhancing their therapeutic efficacy while minimizing cytotoxicity.

Monoclonal antibodies (mAbs) administered intranasally as dry powders can be potentially applied for the treatment or pre-exposure prevention of viral infections in the upper respiratory tract. However, a method to transform the mAbs from liquid to dry powders suitable for intranasal administration and a device that can spray the dry powders to the desired region of the nasal cavity are needed to fully realize the potentials of the mAbs. Herein, we report that thin-film freeze-drying can be applied to prepare aerosolizable mAb dry powders and that the dry powders can be sprayed into the posterior nasal cavity using Aptar Pharmas Unidose (UDS) Powder Nasal Spray System. AUG-3387, a human-derived mAb that neutralizes the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was used in the present study. First, we prepared AUG-3387 thin-film freeze-dried powders (i.e., TFF AUG-3387 powders) from liquid formulations containing different levels of mAbs. The TFF AUG-3387 powder with the highest solid content (i.e., TFF AUG-3387C powder) was then chosen for further characterization, including the evaluation of the plume geometry, spray pattern, and particle size distribution after the powder was sprayed using the UDS Powder device. Finally, the deposition patterns of the TFF AUG-3387C powder sprayed using the UDS Powder device were studied using 3D-printed nasal replica casts based on an adult model and a child model. It is concluded that it is feasible to intranasally deliver mAbs as dry powders by transforming the mAbs into dry powders using thin-film freeze-drying and then spray the powder using the UDS Powder device.

In the past years, we have designed biodegradable poly(benzyl malate) (PMLABe73) homopolymer and amphiphilic poly(ethylene glycol)-b-PMLABe (PEG42-b-PMLABe73) copolymer and several modified (co)polymers to produce biocompatible polymeric nanoparticles (NPs) capable of targeting hepatic cells in vitro with the goal to develop applications in the treatment of liver diseases. The current study aimed at comparing the uptake of PMLABe73 PEG42-b-PMLABe73-based NPs in human hepatic HepaRG cells, primary macrophages and peripheral blood mononuclear cells (PBMC). The uptake of NPs prepared from PEG42-b-PMLABe73 was significantly lower than that of PMLABe73 in both hepatic cells and macrophages. In addition, the NPs uptake by HepaRG cells was inversely correlated to the density of PEG present on their surface. In contrast, the internalization of with PMLABe-based NPs by human macrophages was not affected by low PEG densities, only uptake of fully pegylated PEG42-b-PMLABe73based-NPs was significantly decreased. Herein, we also showed that PMLABe-based NPs did not strongly accumulated in PBMC, T lymphocytes and neutrophils while monocytes showed slightly higher uptake of these NPs. Moreover, we further demonstrated that PMLABe-derived NPs by did not trigger inflammasome activation and secretion of pro-inflammatory cytokines neither in macrophages nor HepaRG cells. Then, we demonstrated that peptide GBVA10-9 derived from George Baker (GB) Virus A, known to exhibit a good hepatotropism did not significantly affect the uptake of PMLABe73-based NPs in HepaRG cells and macrophages, when grafted onto these NPs. The present results demonstrate that PMLABe-derived NPs are very efficiently internalized in both macrophages and hepatocytes but not in PBMC and reinforce our previous reports regarding their biocompatibility.

To achieve their therapeutic effect on the brain, molecules need to pass the blood-brain-barrier (BBB). Many pharmacological treatments of neuropathologies encounter the BBB as a barrier, hindering their effective use. Pharmaceutical nanotechnology based on optimal physicochemical features and taking advantage of naturally occurring permeability mechanisms, nanocarriers such as liposomes offer an attractive alternative to allow drug delivery across the BBB. Liposomes are spherical bilayer lipid-based nanocapsules that can load hydrophilic molecules in their inner compartment and on their outer surface can be functionally modified by peptides, antibodies and polyethyleneglycol (PEG). When composed of cationic lipids, liposomes can serve as gene delivery devices, encapsulating and protecting genetic material from degradation and promoting nonviral cell transfection. In this study, we aimed to develop a liposomal formulation to encapsulate a plasmid harbouring brain-derived neurotrophic factor (BDNF) and infuse these liposomes via the peripheral bloodstream into the brain. To this end, liposomes were tagged with PEG, transferrin, and arginine and characterized regarding their physical properties, such as particle size, zeta-potential and polydispersity index (PDI). Moreover, we selected liposomes preparations for plasmid DNA (pDNA) encapsulation and checked for loading efficiency, in vitro cell uptake, and transfection. The preliminary results from this pilot study revealed that we were able to replicate the liposomes synthesis described in literature, achieving compatible size, charge, PDI, and loading efficiency. However, we could not properly determine whether the conjugation of the surface ligands transferrin and arginine to PEG worked and whether they were attached to the surface of the liposomes. Additionally, we were not able to see transfection in SH-SY5Y cells after 24 or 48 hours of incubation with the pDNA loaded liposomes. In conclusion, we synthesized liposomes encapsulation pBDNF, however, further research will be necessary to address the complete physicochemical characterization of the liposomes. Furthermore, preclinical studies will be helpful to verify transfection efficiency, cytotoxicity, and in the future, safe delivery of BDNF through the BBB.

Background/ObjectivesThe quality and characteristics of approved medicines can vary substantially depending on manufacturing processes and standards within a given country. The aim of the study was to compare the available marketed brands of ademetionine tablets derived from various countries in order to identify potential differences between the different formulations. MethodsWe performed comprehensive analyses of the physical, chemical, and dissolution characteristics of different formulations of ademetionine tablets marketed in China, India, Russia, Ukraine, and Uzbekistan, using the originator formulation of Heptral(R) as the reference standard. The formulations were evaluated at initial analysis and after 3 months at 40{degrees}C/75% relative humidity. Clinical parameters such as ademetionine content, degradation products, S,S-isomer, and water content were assessed using HPLC, and a dissolution profile analysis performed in 2 hours of acid solution followed by 90 minutes in a buffer solution. ResultsThe Nusam (India) and Ximeixin (China) products were the two products most comparable to the Heptral products. Adenomak (Ukraine), the only food-grade product and only one with the tosylate salt showed the most significant quality variations compared to Heptral including dissolution failure as well as considerable variability between batches. ConclusionsThe study highlights the importance of using pharmaceutical-grade ademetionine products to maintain clinical efficacy and ensuring standards are maintained across global markets.

Chronic knee and lower back pain due to osteoarthritis (OA) has a global prevalence and impacts human well-being by impairing mobility. Oxidative stress and inflammation are key factors in OA pathogenesis and progression. Non-viral gene delivery through liposomes is a promising approach for repairing damaged cartilage tissues. Our study focuses on developing co-loaded lipoplexes for efficient co-delivery of curcumin and therapeutic siRNA. Curcumin downregulates many inflammatory cytokines, scavenges free radicals, and upregulates collagen and aggrecan, therefore reducing pain and helping with regeneration. Quality by Design (QbD) principles guided the development of curcumin-loaded cationic liposomes (CL), which were further used as vectors for therapeutic siRNA in the design of the co-loaded lipoplexes. QbD steps involved risk assessment, Design of Experiments (DoE), and selection of the optimal vector, i.e., optimum curcumin-loaded cationic liposomes (Opt-CL), which would ensure the best transfection efficiency for therapeutic siRNA. The efficiency of Opt-CL was evaluated in both the primary chondrocytes and cell lines, which were induced by oxidative stress and inflammatory conditions. The Opt-CL successfully reduced the oxidative stress levels in both. The Opt-CL were complexed with the IL-6 and IL-8 siRNA to form co-loaded lipoplexes, which efficiently reduced the inflammation in the chondrocytes. These co-loaded lipoplexes effectively transfected chondrocytes with no toxicity and are promising for further testing in OA models. The study has yielded an optimal non-viral vector that could serve as a platform for the incorporation of other lipophilic drugs and negatively charged oligonucleotides for various ailments. HighlightsO_LIUtilization of QbD to screen and optimize critical factors for the development of CL C_LIO_LIDevelopment of proof of concept using the curcumin and luciferase siRNA as the small molecule and oligonucleotide candidates for efficient cell viability and transfection C_LIO_LIEvaluation of cell internalization and gene knockdown in a luciferase-expressing chondrocyte cell line to prove the model efficacy C_LIO_LIIn chondrocytes, the optimized formulation demonstrated the reduction of inflammation and oxidative stress. C_LI

AO_SCPLOWBSTRACTC_SCPLOWO_ST_ABSIntroductionC_ST_ABSSome prodrugs are developed in order to improve gastrointestinal absorption properties such as permeability and solubility/dissolution. Prediction of the uptake of prodrugs and their drugs is challening for reasons including gastrointestinal hydrolysis and active transport. Objective and MethodologyThe objective was to use the ANDROMEDA software by Prosilico to predict absorption characteristics - passive fraction absorbed (fa,passive), dose-adjusted dissolution potential (fdiss) and total fa (fa) - of prodrugs and their drugs (including drugs and their active metabolites), and to evaluate how they differ between prodrugs and drugs and the predictive accuracy of the software. Results70 prodrug-drug pairs were found and selected for the study. The mean predicted fa,passive and fdiss for the prodrugs were 0.74 and 0.94, respectively. Corresponding estimates for the drugs were 0.72 and 0.98, respectively. For non-hydrolyzed prodrugs, the median relative and absolute prediction errors for fa were 1.17-fold and 0.08, respectively. Corresponding values for drugs were 1.11-fold and 0.07, respectively. The correlation between predicted and observed fa for non-hydrolyzed ester prodrugs and drugs combined (predictive accuracy) was 0.6. ConclusionProdrugs and drugs had similar average predicted fa,passive and fdiss, and most had or were predicted to have at least 50 % fa. The fa for about 1/3 of non-hydrolyzed prodrugs was higher than for corresponding drugs, showing successful prodrug design. Adequate prediction accuracy validates ANDROMEDA for prediction of prodrug and drug absorption in man.

In recent years radioligand therapy has emerged as an effective treatment modality for various solid malignancies, with pharmacokinetic modeling being routinely used for absorbed dose calculation and patient-specific therapy planning. Exemplary time-activity curves of FAP-targeted radioligands in a mouse model are accurately fitted by a sum of right skew biexponential distributions with four adjustable parameters in total. This type of modeling function is versatile and also suitable for conventional drugs. For further insight, an auxiliary equation is derived that relates tumor clearance to FAP expression and the radioligand dissociation constant.

Teff (Eragrostis tef, family Poaceae) is a native cereal crop widely grown in Ethiopia, containing approximately 73% carbohydrates, of which about 30% is resistant starch. This study evaluates resistant starch extracted from teff grain as a film coating material for colon-targeted delivery of metronidazole, used as a model drug. Starch was extracted from teff and resistant starch was isolated from the total starch. Metronidazole core tablets were prepared by wet granulation, compressed, and coated with a resistant starch-based film. The physicochemical properties of the tablets were evaluated in vitro. To prevent premature film disruption caused by the swelling of amylose, a dominant component of resistant starch, a water-insoluble polymer, ethylcellulose, was added. Various proportions of amylose and ethylcellulose were used as film coating materials and evaluated in simulated conditions to determine the optimal combination for drug release in the colon, but not in the upper gastrointestinal tract. The results of the dissolution and fermentation studies indicated the best film coating proportions of amylose to ethylcellulose and the corresponding thicknesses in percentage of total weight gain were: 1:1 ratio at 6% thickness, 1:2 ratio at 4% and 6% thickness, and 1:3 ratio at 2% and 4% thickness. The targeted drug release of the film material is attributed to bacterial enzyme digestion of the resistant starch component in the colon. The digestion of resistant starch creates pores in the ethylcellulose film scaffold, leading to the disruption of the film and release of the drug exclusively in the colon, where the bacterial microflora reside. Based on these results, resistant starch from teff grain shows potential as a colon-targeting excipient.